Regulatory Harmonization vs. Divergence: A Critical Review of ICH, WHO, and PIC/S in Global Drug Approvals

Abstract

The global pharmaceutical landscape is marked by concerted efforts toward regulatory harmonization through organizations such as the International Council for Harmonisation (ICH), the World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These initiatives aim to standardize technical requirements for drug development, manufacturing, and approval, facilitating faster access to safe and effective medicines worldwide. However, persistent divergences in national regulations, particularly in low- and middle-income countries (LMICs) like those in Africa, undermine these goals, leading to delays, duplicated efforts, and inequities in drug access. This review critically examines the progress and limitations of these harmonization bodies, highlighting challenges such as political barriers, resource constraints, and varying implementation capacities. With a focus on African perspectives, it explores regional initiatives like the African Medicines Regulatory Harmonization (AMRH) and the nascent African Medicines Agency (AMA), underscoring their potential to bridge global-African divides. Drawing on recent developments as of 2025, the paper argues for enhanced reliance mechanisms, transparency, and political commitment to achieve true convergence. Recommendations include tailored capacity-building for African regulators and integration of local manufacturing needs into global standards.